Liposome Drug Delivery Market Analysis

Application (Fungal Diseases, Pain Management, Cancer Therapy, Viral Vaccines, Photodynamic Therapy)

The cancer therapy segment in the liposome drug delivery market is anticipated to hold the largest revenue share of 41% by the end of 2036. This can be attributed to the high prevalence of cancer and the growing demand for advanced therapeutics. As cancer is one of the diseases which attracts more attention from the R&D owing to its high prevalence and seriousness, this segment is anticipated to grow in the upcoming times. According to a report, there were approximately 19.3 million new cancer diagnoses worldwide in 2020, with breast cancer being the most common cancer, followed by lung cancer.

Product (Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B)

The liposomal doxorubicin segment is anticipated to hold 38% share of the global liposome drug delivery market by the end of 2036. This segment includes liposomes that are used to deliver the chemotherapy drug doxorubicin. Liposomal doxorubicin is effective in treating certain types of cancer, such as ovarian and breast cancer which is further expected to contribute to the growth of the segment over the coming decades.

Our in-depth analysis of the global market includes the following segments: